IBT has previously announced its plan to start the phase 3 study in the first half of 2018. Preparations for the study have taken slightly longer than...
The Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 15, 2018 voted to approve the following resolutions: About Infant Bacterial...
Message from the CEO During the past year, IBT passed the most important milestones in the company's history. The company's drug candidate, IBP-9414, which...
Message from the CEO During the past year, IBT passed the most important milestones in the company's history. The company's drug candidate, IBP-9414, which...
The IBT Nomination Committee presented its proposals to the AGM in April 2018, which will be held on May 15, 2018. The Nomination Committee has subsequently...
Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting on Tuesday, May 15, 2018 at 15.00 in the City Conference Ingenjörshuset...
Today, Infant Bacterial Therapeutics AB (publ) publishes the Annual Report for the financial year 2017. The report is available on IBTs website under financial...
Message from the CEO During the last year, IBT passed the most important milestones in the company's history. The company's pharmaceutical candidate, IBP-9414...
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, Singapore, the United States or in...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR CANADA OR IN ANY OTHER JURISDICTION...

Subscribe to our press releases